HUTCHMED Completes Enrollment for China Phase III ORPATHYS–TAGRISSO Lung-Cancer Trial

HUTCHMED said it has finished recruiting patients for its SANOVO Phase III study testing ORPATHYS (savolitinib) in combination with AstraZeneca’s TAGRISSO (osimertinib) as an initial treatment for Chinese patients with EGFR-mutated, MET-overexpressed non-small cell lung cancer. The last participant was enrolled on 18 August, marking completion of a milestone that keeps the programme on track. The randomised, controlled trial compares the dual-targeted regimen with TAGRISSO alone, the current standard of care, and will measure investigator-assessed progression-free survival as its primary endpoint. Secondary goals include overall survival, objective response rate and safety. Top-line data are expected in the second half of 2026. Favourable results could support a supplementary New Drug Application to China’s National Medical Products Administration and expand use of ORPATHYS, which HUTCHMED co-develops with AstraZeneca.